Ocugen, Inc. (OCGN)

NCM – Real vaqt narxi. Valyuta: USD

1.39

+0.02 (1.46%)

Bozor ochiq: Aug 12, 2026, 11:58 AM EDT

1.37

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:59 PM EDT

07.08.2026

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

07.08.2026

Ocugen Q2 Earnings Call Highlights

Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.

06.08.2026

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

06.08.2026

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.05 per share a year ago.

06.08.2026

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (AMD); on track to initiate Phase 3 this quarter Granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA for OCU410, enabling eligibility for priority review and accelerated approval Signed a binding term sheet with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, to negotiate an exclusive license for OCU400 in retinitis pigmentosa (RP) across the Middle East and North Africa (MENA) region Successfully completed OCU400 Process Performance Qualification (PPQ) batches, supporting Biologics License Application (BLA) and commercial launch supplies Closed $130.0 million convertible senior notes financing, extending cash runway into 2028 Remain on track to announce top-line results for two late-stage clinical programs, OCU400 for RP and OCU410ST for Stargardt disease in 1Q 2027 and 2Q 2027, respectively Strengthened leadership team with the appointments of Mohamed Genead, M.D.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Ocugen, Inc. (OCGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ocugen, Inc. (OCGN)

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen Q2 Earnings Call Highlights

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen Q2 Earnings Call Highlights

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Search stocks

Ocugen, Inc. (OCGN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ocugen, Inc. (OCGN)

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen Q2 Earnings Call Highlights

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen Q2 Earnings Call Highlights

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Videolar

No Data

Press-relizlar

Ocugen Provides Business Update with Second Quarter 2026 Financial Results